Cel­gene antes up $195M more to stay close to For­ma, adding neu­rode­gen­er­a­tion fo­cus

What­ev­er Cel­gene $CELG learned dur­ing its lengthy col­lab­o­ra­tion with For­ma Ther­a­peu­tics must have been promis­ing. The big biotech is dou­bling down on For­ma, ex­tend­ing its pact and pick­ing up an op­tion to broad­en the scope of their re­search work, with For­ma adding new drugs fo­cused on pro­tein home­osta­sis, in­flam­ma­tion/im­munol­o­gy and neu­rode­gen­er­a­tion.

Cel­gene is pay­ing For­ma $195 mil­lion up­front for the ex­tend­ed re­la­tion­ship, hand­ing Cel­gene ex-US rights on drug can­di­dates through Oc­to­ber 1, 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER